ATE501710T1 - Somatostatin-analog-formulierungen - Google Patents

Somatostatin-analog-formulierungen

Info

Publication number
ATE501710T1
ATE501710T1 AT05818366T AT05818366T ATE501710T1 AT E501710 T1 ATE501710 T1 AT E501710T1 AT 05818366 T AT05818366 T AT 05818366T AT 05818366 T AT05818366 T AT 05818366T AT E501710 T1 ATE501710 T1 AT E501710T1
Authority
AT
Austria
Prior art keywords
formulations
somatostatin analog
somatostatin
administration
analog formulations
Prior art date
Application number
AT05818366T
Other languages
English (en)
Inventor
Fredrik Joabsson
Markus Johnsson
Andreas Norlin
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500807A external-priority patent/GB0500807D0/en
Priority claimed from GB0507811A external-priority patent/GB0507811D0/en
Priority claimed from PCT/GB2005/002217 external-priority patent/WO2005117830A1/en
Priority claimed from GB0518878A external-priority patent/GB0518878D0/en
Application filed by Camurus Ab filed Critical Camurus Ab
Priority claimed from PCT/GB2005/004748 external-priority patent/WO2006075124A1/en
Application granted granted Critical
Publication of ATE501710T1 publication Critical patent/ATE501710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT05818366T 2005-01-14 2005-12-09 Somatostatin-analog-formulierungen ATE501710T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0500807A GB0500807D0 (en) 2005-01-14 2005-01-14 Formulation
GB0507811A GB0507811D0 (en) 2005-04-18 2005-04-18 Formulation
PCT/GB2005/002217 WO2005117830A1 (en) 2004-06-04 2005-06-06 Liquid depot formulations
GB0518878A GB0518878D0 (en) 2005-09-15 2005-09-15 Formulations
PCT/GB2005/004748 WO2006075124A1 (en) 2005-01-14 2005-12-09 Somatostatin analogue formulations

Publications (1)

Publication Number Publication Date
ATE501710T1 true ATE501710T1 (de) 2011-04-15

Family

ID=40432504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05818366T ATE501710T1 (de) 2005-01-14 2005-12-09 Somatostatin-analog-formulierungen

Country Status (3)

Country Link
US (1) US8871712B2 (de)
AT (1) ATE501710T1 (de)
DE (1) DE602005026998D1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
SI1845942T1 (sl) 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
DK1888031T3 (da) * 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
ES2834318T3 (es) 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
AU2017336199B2 (en) * 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
WO2018067987A1 (en) * 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
EP3551210A1 (de) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulatoren der komplementaktivität
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US595502A (en) * 1897-12-14 terpeningt
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) * 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
EP0643620B1 (de) * 1991-10-04 1999-07-21 Gs Development Ab Teilchen, methode zur herstellung der teilchen und deren verwendung
US6228383B1 (en) * 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
ES2135723T3 (es) 1994-03-30 1999-11-01 Gs Dev Ab Uso de esteres de acidos grasos como sustancias bioadhesivas.
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) * 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
JPH11513393A (ja) 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0839525B1 (de) * 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter Freisetzung
CA2286052A1 (en) 1997-04-17 1998-10-29 Lise Sylvest Nielsen A novel bioadhesive drug delivery system based on liquid crystals
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SI1140148T1 (sl) 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
EP1408932A4 (de) * 2001-06-23 2009-02-25 Lyotropic Therapeutics Inc Teilchen mit verbesserter solubilisierungseigenschaft
EP1412384B1 (de) 2001-06-28 2007-12-26 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
JP2007501213A (ja) * 2003-08-04 2007-01-25 カムルス エービー 両親媒性粒子に活性因子を装填する方法
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
GB0322033D0 (en) * 2003-09-19 2003-10-22 Camurus Ab Composition
AU2005324794C1 (en) 2003-11-07 2010-12-02 Camurus Ab Somatostatin analogue formulations
EP1682091B1 (de) * 2003-11-07 2017-03-29 Camurus Ab Zusammensetzungen von lipiden und kationischen peptiden
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
CA2554052C (en) 2004-01-23 2013-10-22 Camurus Ab Ternary non-lamellar lipid compositions of structure forming amphiphile, structure swelling amphiphile and dispersion stabilising amphiphile
GB0401513D0 (en) * 2004-01-23 2004-02-25 Camurus Ab Compositions
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
EP1778187B1 (de) * 2004-08-04 2012-05-23 Camurus Ab Nichtlamellare dispersionen bildende zusammensetzungen
SI1845942T1 (sl) * 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
EP1848403B8 (de) 2005-01-14 2010-05-19 Camurus Ab Topische bioadhäsive formulierungen
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
DK1888031T3 (da) * 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
CN103071209A (zh) * 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations

Also Published As

Publication number Publication date
DE602005026998D1 (de) 2011-04-28
US8871712B2 (en) 2014-10-28
US20090069221A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
PH12013502550A1 (en) Controlled release peptide formulations
ATE501710T1 (de) Somatostatin-analog-formulierungen
PE20050919A1 (es) Agente endoparasiticida para administracion topica
MX350929B (es) Formulaciones peptidicas robustas de liberación controlada.
DK1845942T3 (da) GNRH-analogformuleringer
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
ATE401054T1 (de) Flüssige depotformulierungen
BRPI0607762B8 (pt) análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto
UY27740A1 (es) Nuevos compuestos
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
NO20070983L (no) Stabil injiserbar blanding av alfa-tokoferylsuksinat, analoger og salter derav
MX2018003333A (es) Formulaciones de liberacion controlada.
AR019262A1 (es) Proceso para la preparacion de una formulacion que comprende una sustancia activa o sustancias activas asociadas con un portador, y formulacion preparadapor dicho proceso.
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
EA201791166A1 (ru) Препараты с контролируемым высвобождением
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
PA8800101A1 (es) Producto de dispersion sólida que contiene un compuesto a base de n-aril urea
PH12014502614A1 (en) Somatostatin receptor agonist formulations
PA8633601A1 (es) Profarmacos de esteroides con accion androgenica
ES2171591T3 (es) Nueva forma de dosificacion de hidroxocobalamina y su uso en el envenenamiento por cianuro.
CL2004000978A1 (es) Compuestos derivados de pirazolopirimidinas sustituidos de formula definida, inhibidores de pde; procedimiento para su preparacion; composicion farmaceutica que los contiene y sus usos para preparar medicamentos que sirven para tratar trastornos de l
UY28370A1 (es) Agentes terapéuticos
GT199700113A (es) Tetrahidro - 6h - pirazino ( 1, 2 - b ) isoquinolin - 1, 4 - dionas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties